Medincell Stock Soars 5% and Challenges its Resistance at €28.52
The biotech company from Montpellier accelerates sharply mid-morning, extending the rebound that began late last week. The stock is among the top performers in the SBF 120 in a rising Parisian market.
Significant Gain During the Session
Medincell stock increases by 5.03% to €28.40 during the session, after closing at €27.04 the previous day. The stock is among the strongest risers in the SBF 120, as the broader index is up by 0.40%. This movement amplifies the rebound seen in recent sessions, with a gain of 13.3% over a week and nearly 28% over three months. The price is now significantly above its three moving averages, with a gap of +7.7% over the MM20 (€26.38), +8.4% over the MM50 (€26.19), and +8.5% over the MM200 (€26.18), with all three curves tightened in the same zone. The stock is testing its resistance threshold at €28.52, while the RSI at 54 remains neutral. A sustained crossing of this threshold would pave the way for a continuation of the movement.
A Rebound Following the Digestion of Mid-June Annual Accounts
The rebound occurs as the stock is still digesting the annual accounts published on June 16, which had heavily penalized the value. The report showed a net loss widened to €31.3 million despite Uzedy royalties increasing by 42% to €9.3 million. Over a year, the performance remains strong with a gain close to 70%. During this announcement, the company highlighted the continued ramp-up of Uzedy royalties and the expected commercial launch of Olanzapine LAI in the fourth quarter of 2026 as its growth levers. The anticipated increase in operating expenses to support this expansion was among the points of attention identified. The resistance threshold of €28.52, now in contact with the current price, constitutes the central technical level of the current movement.
